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Abstract 
 
The role of heat-stable enterotoxin receptor guanylyl cyclase C (GCC) is well known for its 
aberrant chloride conductance in the intestinal epithelium in response to bacterial infection. 
Recently, its use as a molecular marker to detect metastatic colon cancer has grown, as has its 
use as oral hormone therapy for tumor suppression. This study investigates the preliminary 
stages of a DNA dendritic cell-based vaccine development specific to targeting guanylyl cyclase 
in systemic tissues. Construction of the plasmid as well as its transduction to Class I MHC 
molecules in antigen-presenting dendritic cells is examined. Future exploration includes a 
comparative assessment of prophylactic and therapeutic treatments. 
 
 
Introduction  
 
Guanylyl Cyclases  
 
Few classes of enzymes are as diversified and interconnected as the guanylyl cyclase family. 
Guanylyl cyclases (GCs) catalyze the conversion of 5’GTP to cGMP,  a common second-
messenger molecule with regional differing expression
1
. Increasingly in recent years, various 
members of the family have been the target of pharmaceutical therapeutic treatments due to their 
potential as versatile receptors and downstream modifier
2
. In the mammalian body, four soluble 
subunits, α1, α2, β1, and β2 and seven single membrane-spanning integral subunits: GC-A, GC-B, 
GC-C, GC-D, GC-E, GC-F, GC-G, are expressed 
3
. However, only three of the four soluble 
subunits and five of the seven single membrane-spanning subunits are active in the human body
3
. 
Particular differentiated tissues, such as the lung, brain, kidney and vasculature, harbor higher 
concentrations of soluble GCs than other tissues in the body 
4
. Soluble GCs are the receptors for 
nitric oxide in smooth muscle vasculature, and following activation conduct platelet aggregation 
inhibition and vasodilatation
5-12
.  
 
In contrast to nitric oxide for soluble GCs, peptides are recognized as the predominant activators 
of transmembrane GCs
3
. GC-A is expressed vigorously in the brain, liver, testis, vasculature, 
adrenals, kidneys, lungs, and adipose tissues and less so in the heart and mesentery 
13-18
. Its 
activity prevents cardiac hypertrophy, hypertension, and ventricular fibrosis
19,20
. Activation 
occurs by atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP); hormonal 
activation occurs by phosphorylation 
21,22
. GC-B is expressed principally in reproductive tissues, 
bones, lungs, heart, brain, fibroblasts and vasculature smooth muscle
16,23,24
. However, it is best 
known for inducing growth and oocyte maturation
25,26
. In those respective tissues, C-type 
natriuretic peptide (CNP) activates GC-B in a paracrine manner
27
. GC-D, activated by carbon 
dioxide, bicarbonate
28-30
, uroguanylin and guanylin 
31
, is well established in the nasal epithelium 
and influences food preference
32
. GC-E is found exclusively in the pineal gland, while GC-E and 
GC-F are both found in the retina
33
. While extracellular hormones sufficiently activates the other 
membrane-spanning guanylyl cyclases, GC-E and GC-F rely on guanylyl cyclase activator 
proteins (GCAPs) for regulation
34-36
. Upon activation, GC-E is required for recovery of the dark 
state after phototransduction
37,38
. The two cyclases also support rod and cone nourishment, 
thereby preventing blindness, as well as phototransduction for sensory input 
39
. Finally, GC-G is 
located primarily in skeletal muscle, bone, lungs and the testes
40-42
. However, recently its 
chemosensory function in Grueneberg ganglion neurons in the nasal epithelia upon activation by 
bicarbonate was identified
43
.  
 
 
Guanylyl Cyclase-C  
 
Guanylyl Cyclase C (GCC) is a transmembrane receptor structurally analogous to GC-A and 
GC-B 
44
 that binds endogenous peptides uroguanylin (UGN) and guanylin (GN), intracellular 
peptide cGMP, as well as the bacterial heat-stable enterotoxin (STa) 
45-47
. Expression in humans 
is restricted to intestinal mucosal cells 
48,49
. Yet in other species, its presence has been identified 
in the perinatal liver
50
, lung, gall bladder, testes 
51
, mesentery, atrium, and kidney
16,52
. 
 
In normal physiological activity, cGMP concentrations increase after the ligands uroguanylin and 
guanylin bind, phosphorylating the cystic fibrosis conductance receptor, and increasing chloride 
flow into the lumen 
45,53,54
. Enterotoxins released by diarrheagenic bacteria such as Citrobacter 
freundii, Escherichia coli, Vibrio cholerae, Yersinia enterocolitica, and Vibrio mimicus bind to 
the GC-C receptor, inducing chloride and water flow into the lumen, resulting in diarrhea
54,55
. 
Inhibition of guanylyl cyclase-C signaling prevents chloride and subsequent water secretion, 
invoking potential for therapeutic strategies in developing countries where diarrhea is an 
endemic issue 
56
. 
 
 
Guanylyl Cyclase-C and Tumorigenesis  
GC-C regulates intestinal epithelial proliferation at the G1/S phase intersection of the mitotic 
cycle and prevents somatic hypermutation 
57
.Elimination of GC-C results in a decrease in the 
proportion of differentiated cells, a marked increase in growth along the crypt-villus axis, 
increased migration, and an increase in the rate of hypermutation 
5758
. Additionally, expression of 
uroguanylin 
59
 and guanylin 
60,61
is significantly decreased. This apparent decrease in uroguanylin 
and guanylin signaling to GC-C at the site of adenoma is likely responsible for 
carcinogenesis
57,58,60,62
. GC-C in both primary and metastatic tumors is not only apparent 
63,64
, 
but vigorously overexpressed due to a lack of its endogenous ligands uroguanylin and guanylin 
57,58,62,65,66
. Astoundingly, a lack of GC-C is associated with a considerable decrease in the 
number of adenomas and an increase in apoptosis in the proximal intestine
67
.  
 
 
Guanylyl Cyclase C Related Therapeutics  
 
In the past two decades, therapeutic approaches to targeting colorectal cancer metastasis has 
focused on functional STa receptors such as GC-C, due to its exclusive presence in the intestinal 
epithelium and its abnormal overexpression in tandem with adenocarcinoma indicators 
63,65
. One 
of the most direct approaches is administration of GC-C via oral hormone therapy due to 
evidence of its tumor suppressing activity 
62,65,66,68,69
. Although GC-C prevents metastasis in the 
intestinal epithelium by way of colon cancer cell MMP-9 regulation
70
, the presence of GC-C in 
extraintestinal organs detected by reverse transcriptase PCR is considered a more sensitive and 
specific indicator of metastasis than histopathology alone 
64,71
. In stage II colorectal cancer 
patients, the presence of guanylyl cyclase C mRNA in lymph nodes is consistent with recurrence 
71,72
. Stage II cancers in patients without GCC mRNA lymph node presence did not recur 
72
. 
 
 
Dendritic Cell Based Immunotherapy  
 
Dendritic cells (DCs) are antigen-presenting cells, first described in 1973 by Steinman and Cohn, 
that sample various antigens in the surrounding environment 
73
. Their presence is significantly 
more distinguished in epithelial tissues, such as the skin, lungs, and intestinal lining, where they 
monitor for foreign pathogens 
74-77
 and activate B cells and T cells much more effectively than 
other cell types such as B lymphocytes, T lymphocytes, and macrophages 
78.79
. In particular, 
dendritic cells present phagocytosed antigen on Class II Major Histocompatability Complexes 
(MHC) to immature T-cells 
79,80
. MHC Class I molecules are typically loaded with peptides 
excised from internal cytosolic antigens 
81
, however they can also present peptides from 
phagocytosis of bacteria 
82
, and apoptosis of other cells 
83
.  
 
Immature DCs use two mechanisms to capture the antigens which they present: constitutive 
macropinoctyosis and micropinocytosis of large volumes of fluid, as well as macrophage-
mannose receptor (MMR) mediated capture. Macro and micropinocytosis are insatiable 
mechanisms of antigen capture, while MMR mediated capture is satiable and more selective to 
specific antigens 
84
. Activation occurs by Toll-like receptors (TLR), cytokine receptors, TNF-
receptors, FcR receptors, and sensors for cell death 
85
. Indeed, tumor Necrosis Factor alpha 
(TNF-α) or soluble CD40 ligand (CD40L) causes a notable increased surface expression of MHC 
Class I and MHC Class II molecules, B7 and ICAM-1 
86
.  
 
Upon DC activation and maturation, MHC Class II molecules present peptide fragments to CD 
4+ helper T-cells, while MHC Class I molecules present peptide fragments to CD 8+ cytotoxic T-
cells
85
.  T-cell activation typically requires a cell activation signal, provided by inflammatory 
cytokines TNF-α or IL-1, or bacterial components such as LPS. The signal induces MHC and co-
stimulation receptor surface expression and cell migration to secondary lymphoid organs for T 
cell priming 
87
.  
 
In recent years, a growing emphasis has been placed on dendritic cell based immunotherapy due 
to its potential to reduce tumor size, and prevent recurrence by generating immunological 
memory in a therapeutic approach. On the other hand, it would be equally beneficial to prevent 
metastasis in the first place through a prophylactic approach 
88
.  
Materials and Methods 
 
 
pEF1-VP22-mGCC-S1 Plasmid Construction 
 
Digestion with Enzymes Not1, XBa 
 
pEF1-VP22 vector plasmid and pCR-II-TOPO-mGCC-S1 insert plasmid were obtained. Two 
overnight digestion mixtures were prepared with 5 μL 10X enzyme buffer, 5 μL pEF1-VP22, 2.5 
μL XBa, 2.5 μL Not1, and 35 μL water for a total volume of 50 μL. Digestions were loaded onto 
a 50 mL 0.7% agarose gel and run for approximately an hour at 80V. The gel was stained, 
destained, and excised under ultraviolet light. Excision of pEF1-VP22 and mGCC bands with 
desired lengths was completed with sterile scalpels. The weight in milligrams was obtained of 
the gel bands. Plasmids then underwent purification by centrifugation using the ProMega DNA 
Centrifugation by Purification protocol. 10 mL Membrane Binding Solution was added per 10 
mg of gel. The gel was incubated at 56 C for 10 minutes to dissolve the gel. Concentrations of 
pEF1-VP22 and mGCC-S1 insert were determined using photometry.  
 
pEF1-VP22 underwent dephosphorylation after purification to ensure successful ligation. 1 μL 
shrimp-alkaline phosphatase, 5 μL 10X enzyme buffer, 20 μL pEF1-VP22, and 24 μL water for a 
total volume of 50 μL. Dephosphorylation mixture was incubated at 37˚C. After 1 hour, the 
dephosphorylation enzymes were inactivated, and the vector isolated.  
 
Dephosphorylation inactivation occurred with placement of pEF1-VP22 dephosphorylation 
mixture at 65˚C for 15 minutes. 50 μL of 25:1 Phenol / Chloroform and 50 μL dephosphorylation 
were combined to create a new mixture that was emulsified via spinner. The 100 μL 
consequential mixture was transferred to a prepared 2 mL phase lock gel and centrifuged at 
14,000 rpm for 5 minutes. A 1:1 volume of chloroform / isoamyl was added to the mixture, and 
emulsified for 10 minutes via spinner. The 200 μL consequential mixture was centrifuged at 
14,000 rpm for 5 minutes. The aqueous phase containing the  pEF1-VP22 plasmid was 
harvested.  
 
The pEF1-VP22  vector was precipitated from the aqueous phase by adding 2.5x volume -20 C 
ethanol and incubated in a -70˚C ice bath for 15 minutes. 0.1x volume ammonium acetate salt 
was added. The mixture was centrifuged at 16000 rpm for 15 minutes, and ethanol supernatant 
discarded. 1 mL 70% ethanol was added and the entire mixture centrifuged at 16000 rpm for 15 
minutes and supernatant discarded. The process was repeated. The pellet was dried and 
resuspended in nuclease free water. Concentration of pEF1-VP22 was measured with 
photometry.  
 
Figure 1 - Plasmid map of vector pEF1-VP22 used for ligation. Highlighted in red boxes are 
digestion sites for Not1 at 915 bp and XBa at 927 bp.  
 
Figure 2 - Plasmid map of insert pCR-II-TOPO-mGCC-S1 used for ligation. Highlighted are the 
Not1 and XBa digestion sites at 3 bp and 1402 bp respectively used for the primary approach. 
Also highlighted is another Not1 digestion site at 1441 bp used in the alternative approach.  
 
Figure 3 - Plasmid map of pEF1-VP22-mtGNAQ-PADRE vector, used in the alternative 
approach. The mtGNAQ-PADRE was extracted using Not1 digestion sites at 915 bp and 2077 
bp.  
 
Figure 4 - Plasmid map of pEF1-VP22-mGCC-S1, the desired plasmid expressed in dendritic 
cells. The mGCC-S1 segment was inserted using Not1 digestion sites at 915 bp and 2353 bp.  
 
 
 
Digestion with Enzyme Not1 Using Alternative Vector 
 
An alternate approach attempted was using the pEF1-VP22-mtGNAQ-PADRE plasmid to 
construct a vector and pCR-II-TOPO-mGCC-S1 as an insert. Two overnight digestion mixtures 
were prepared with possible digestion mixtures were prepared with 5 μL 10X enzyme buffer, 5 
μL pEF1-VP22-mtGNAQ-PADRE, 5 μL Not1, and 35 μL water for a total volume of 50 μL. 
Digestions were loaded onto a 50 mL 0.7% agarose gel and run for approximately an hour at 
80V. The gel was stained, destained, and excised under ultraviolet light. Excision of pEF1-VP22 
and mGCC-S1 bands with desired lengths was completed with sterile scalpels. Plasmids then 
underwent purification by centrifugation. Concentrations of pEF1-VP22 and mGCC-S1 insert 
were determined using photometry. 
 
pEF1-VP22 underwent dephosphorylation after purification to ensure successful ligation. 1 μL 
shrimp-alkaline phosphatase, 5 μL 10X enzyme buffer, 20 μL pEF1-VP22, and 24 μL water for a 
total volume of 50 μL. Dephosphorylation mixture was incubated at 37˚C. After 1 hour, the 
dephosphorylation enzymes were inactivated, and the vector isolated. Dephosphorylation 
inactivation occurred with placement of pEF1-VP22 dephosphorylation mixture at 65˚C for 15 
minutes.  
 
The pEF1-VP22 vector was then isolated by gel extraction in a 50 mL 0.7% agarose gel run at 
80V for approximately 60 minutes. The vector was purified by centrifugation.  
 
 
Ligation and Transformation 
 
Two ligation mixtures were prepared, one with purified pEF1-VP22 and mGCC-S1 insert 
fragments, and the other solely with pEF1-VP22 for self-ligation. The appropriate amounts of 
insert mGCC-S1 and vector pEF1-VP22 used in ligation were calculated based on a formula 
shown below: 
Formula: ng insert =     x molar ratio of   
 
The insert to vector 3:1 was used for ligation. The ligation mixture was prepared with 1 μL 
pEF1-VP22, 1 μL mGCC-S1 insert, 1 μL 10X enzyme buffer, 1 μL ligase, 6 μL water for a total 
volume of 10 μL. The self-ligation mixture was prepared with 2 μL pEF1-VP22, 1 μL 10X 
enzyme buffer, 1 μL ligase, 6 μL water for a total volume of 10 μL. Ligation occurred overnight 
at 16ºC. 
 
Electroporation occurred at 1.5 kV with the objective of inserting the pEF1-VP22-mGCC-S1 
ligation plasmid into bacteria. Standard electroporation mixtures were prepared for both the 
pEF1-VP22/mGCC-S1 ligation and the pEF1-VP22 self-ligation. Electroporation mixtures 
including 1 μL ligation mixture, 4 μL water, 20 μL 10% glycerol and 25 μL ampicillin-resistant 
bacteria were inserted into cuvettes. Immediately after electroporation, 600 μL SOC was added 
to the cuvettes, and the entire mixture transferred to a bacterial tube for incubation at 37˚C for 1 
hour. After incubation, 100 μL of bacteria containing pEF1-VP22-mGCC-S1 ligation plasmid 
was plated onto ampicillin-resistant agar and incubated at 37˚C overnight. Within 24 hours, 
plates were checked for colony growth. Ligation of pEF1-VP22 with the mGCC-S1 insert was 
confirmed with comparison to self-ligation. The ligation would contain colonies, whereas the 
self-ligation would not.  
 
 
Mini-Prep of Select Colonies for pEF1-VP22-mGCC-S1 Verification 
 
Once ligation presence was confirmed with bacterial colony presence, sterile toothpicks were 
used to transfer select colonies to bacterial tubes containing 3 mL ampicillin-resistant liquid agar 
for overnight incubation at 37 C. After incubation, bacterial tubes were centrifuged at 4000 rpm 
for 10 minutes. Supernatant was discarded and bacterial pellet resuspended. Sterile toothpicks 
were used to swipe each colony onto its respective space on a master plate. Bacteria was 
resuspended in 600 μL water, and combined with 100 μL celll lysis buffer, subsequently 300 μL 
neutrilization solution and centrifuged at 14000 rpm for 3 minutes. Supernatant was collected 
and eluted through columns into collection tubes using centrifugation at 14000 rpm. Afterwards, 
200 μL of Endotoxin Removal Wash was added to each column and eluted by centrifugation. 400 
μL Column Wash was then added and eluted through each column by centrifugation. Then 30 μL 
of distilled water was eluted through the column by centrifugation. Bacterial colony plasmids 
were loaded into a 30 mL 0.7% agarose gel and run for approximately 60 minutes at 80 V for 
DNA length confirmation.  
 
 
Dendritic Cell Nucleofection of Green Fluorescent Protein, Red Fluorescent Protein, pEF1-
VP22-mGCC-S1 plasmid 
 
Mouse femurs were harvested and immature dendritic cells flushed out via syringe with RPMI 
1640 supplemented with culture medium II (10% fetal calf serum, 100 μg/ml streptomycin, 100 
U/ml penicillin, 2 mM glutamine). Cells were centrifuged at 300xg for 10 minutes at room 
temperature, resuspended until at a density of 1x10
6
 cells / mL and transferred to 24-well plates 
for incubation at 37ºC for six days.  
 
On Day 2, 700 μL was replaced with culture medium I (10% fetal calf serum, 100 μg/ml 
streptomycin, 100 U/ml penicillin, 2 mM glutamine and 2000U/ml GM-CSF). On Day 3, all of 
the culture medium was removed and the wells washed multiple times in 500 μL culture medium 
I. 1 mL fresh culture medium I was added to each well. On Day 6, loosely adherent immature 
dendritic cells were harvested by pipetting with culture medium I.  
 
 
Maturation of Dendritic Cells 
 
Mature dendritic cells were generated by stimulating immature dendritic cells with 0.1 μg/ml 
LPS. 1 mL maturation media replaced 1 mL of cell supernatant. On Day 7, loosely adherent 
mature dendritic cells were harvested by pipetting with culture medium I. 
 
 
 
 Nucleofection 
 
In preparation for nucleofection, 48-well plates were filled with 400 μL culture medium I and 
incubated at 37˚C. Cells were centrifuged at 300xg for 10 minutes after determining cell density. 
Supernatant was discarded entirely and the pellet resuspended in 100 μL room temperature 
Nucleofector Solution. 100 μL room temperature Nucleofector Solution was combined with 5 
different DNA plasmids examined for expression: 2 μg pEF1-VP22-mGCC-S1 plasmid from 
Colony 1, 2 μg pEF1-VP22-mGCC-S1 plasmid from Colony 2, 2 μg pmax pMax-GFP Vector, 2 
μg pmax RFP Vector, and 2 μg pEF1-VP22-mtGNAQ-PADRE-S1 as a control. Cell Solution 
with DNA was transferred to cuvette and run under Nucleofector Program Y-001. 400 μL culture 
medium I was added to the cuvette immediately after nucleofection. Sample was transferred to a 
48-well plate. Nucleofection had occured according to Lonza Amaxa Mouse Dendritic Cell 
Nucleofector Kit for Immature and Mature Dendritic Cells. Cells were stained with anti-CD11C-
PE antibodies, imaged, and analyzed via flow cytometry (FACS Analysis) 
 
 
Results 
 
pEF1-VP22-mGCC-S1 Construction 
 
Not1 / XBa double digestion fragment lengths for gel excision were 6722 bp for pEF1-VP22, 
and 1399 bp for the mGCC-S1 insert. However, the double digest approach did not generate 
bacterial colonies upon transformation multiple times. On several instances, Not1 / XBa did in 
fact generate bacterial colonies. The plasmids from these colonies underwent MiniPrep plasmid 
isolation and digested with enzymes BamH1 and HindIII for 3 hours at 37˚C in separate 
reactions. Upon analysis of the fragment lengths on agarose gel, it was determined there were no 
viable candidates for further pursuit.  
 
Not1 digestion fragment lengths for gel excision were 6969 bp for pEF1-VP22 and 1438 for the 
mGCC-S1 insert. The alternate approach using the pEF1-VP22-mtGNAQ-PADRE-S1 vector 
yielded several bacterial colonies. The plasmids from these colonies, upon MiniPrep and 
digestion with enzymes BamH1 and HindIII, yielded expected fragment lengths. Due to the 
potential for presence of the desired plasmid, a multi-digest was performed with bacterial 
colonies 1,2 and 6 from the MiniPrep. The multi-digest consisted of separate reactions with 
enzymes HindIII, BamH1, Not1, ApaL1, and BglII for clone 1, and HindIII, BamH1, Not1, and 
BglII for clones 2 and 6. Fragment lengths for Not1 digestion yielded fragment lengths 6969 bp 
for pEF1-VP22 and 1438 for the mGCC-S1 insert. Colony 1 and Colony 2 had the largest 
presence of the apparent plasmid pEF1-VP22-mGCC-S1, and were thus used for nucleofection. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Gel excision of pEF1-VP22  Figure 2 - Gel excision of pEF1-vector and 
mGCC-S1 insert (Not1 Digestion)    VP22 vector and mGCC-S1 insert  
        (Not1/XBa Digestion) 
Lane 1 - DNA 1 kb Ladder    Lane 1 - DNA 1 kb Ladder 
Lane 2 - pEF1 - VP22 - S1 (6969 bp)   Lane 2 - pEF1 - VP22 - S1 (6722 bp)  
Lane 3 - mGCC-S1 (1438 bp)   Lane 3 - mGCC-S1(1399 bp) 
 
Figure 3 
 
MiniPrep of ligated clones using Not1 digestion/ 
pEF1-VP22-mtGNAQ-S1 vector. 
 
Upper - Hind III Digestion 
Lane 1  - DNA 1 kb Ladder 
Lane 2 - Clone 1, Lane 3 - Clone 2, Lane 4 - Clone 3, 
Lane 5 - Clone 4, Lane 6 - Clone 5, Lane 7 - Clone 6, 
Lane 8 - Clone 7 
 
 
Lower - Bam H1 Digestion 
Lane 1 - DNA l kb Ladder, Lane 2 - Clone 1, Lane 3 - 
Clone 2, Lane 4 - Clone 3, Lane 5 - Clone 4, Lane 6 - 
Clone 5, Lane 7 - Clone 6, Lane 8 - Clone 7 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 - MultiDigest of Clones 1, 2, and 6 from MiniPrep after ligation to confirm presence of 
desired pEF1-VP22-mGCC-S1 plasmid. Clone 1: Lanes 2-6; Lane 2 - HindIII, Lane 3 - BamH1, 
Lane 4 - Not1, Lane 5 - ApaL1, Lane 6 - BgLII, Clone 2: Lanes 8-11; Lane 8 - HindIII, Lane 9 - 
BamH1, Lane 10-Not1, Lane 11-BgLII,  Clone 3: Lanes 13-16; Lane 13-HindIII, Lane 14-Lane-
BamH1, Lane 15-Not1, Lane 16-BgLII   Of particular interest is Not1, which for all three clones 
displays the expected size lengths of 6969 for pEF1-VP22-mGCC-S1 and 1438 for the mGCC-
S1 insert.   
 
 
FACS Analysis of RFP, GFP, and CD11C 
 
Protein expression efficacy of dendritic cells nucleofected with pMaxGFP and pMaxGFP was 
determined by counting fluorescent cells per field 24 hours after nucleofection and ranged from 
23.8% (pMaxRFP) to 49% (pMaxGFP). Analysis of cell differentiation revealed that in control 
cells, 6% demonstrated GFP fluorescence to gate threshold levels and 9% demonstrated 
phycoerithrine (PE) fluorescence to gate threshold levels. In cells labeled with CD11c-PE 
antibodies, 4.8% of dendritic cells demonstrated GFP fluorescence to gate threshold levels and 
84.8% demonstrated PE (and thus CD11c) fluorescence to gate threshold levels. Analysis of 
protein expression after nucleofection elucidated that in cells nucleofected with pMax RFP, 0.5% 
demonstrated GFP fluorescence to gate threshold levels, and 23.8% for RFP fluorescence to gate 
threshold levels. In cells nucleofected with pMax GFP, 49% demonstrated GFP fluorescence to 
gate threshold levels and 95.5% demonstated antibody CD11c-PE fluorescence to gate threshold 
levels.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 - Panels (from left to right) 1 and 2: pMaxGFP fluorescent expression in dendritic cells 
(49% efficacy), Panel 3: pMax-RFP expression (23.8% efficacy), Panels 4 and 5: bright field of 
pMaxGFP expression, Panel 6: magnification of pMaxGFP fluorescent expression. 
 
 
 
 
Figure 6 - FACS analysis of cell differentiation. 6% fluorescence significant for pMax-GFP on 
left. 9% fluorescence significant for phycoerithrine (PE) on right.  
Figure 7 - FACS analysis of cell differentiation. 4.8% fluorescence significant for pMax-GFP on 
left. 84.8% fluorescence significant for phycoerithrine (PE) on right.  
Figure 8 - FACS analysis of protein expression post-nucleofection . 0.5% fluorescence 
significant for pMax-GFP on left. 23.8% fluorescence significant for pMax-RFP on right. 
Figure 9 - FACS analysis of protein expression post-nucleofection . 49% fluorescence 
significant for pMax-GFP on left. 95.5% fluorescence significant for CDC11c-PE on right. 
 
 
 
 
Discussion 
 
While the reason for its dysfunction remains unclear, the primary double digest with Not1 and 
XBa is not recommended for construction of the desired pEF1-VP22-mGCC-S1 plasmid. Gel 
excision ascertained pEF1-VP22 and mGCC-S1 were present in ample quantities. However, after 
multiple ligations and transformations, growth of bacterial colonies was scarce and amorphous. 
The plasmid strains in the few colonies present, after digestion with enzymes BamH1 and 
HindIII, did not yield expected fragment lengths. 
 On the other hand, the alternative use of Not1 with two digestion sites on the pEF1-VP22-
mtGNAQ-PADRE vector and the pCR-pCR-II-TOPO-mGCC-S1 insert proved more successful. 
Gel excision confirmed pEF1-VP22 and mGCC-S1 were present in ample quantities. Upon 
ligation, clearly defined colonies were present in greater numbers than in the primary approach.  
From the MultiDigest, it’s apparent that the desired pEF1-VP22-mGCC-S1 plasmid may be 
present. Not1 digest revealed expected fragment lengths (6969 bp for the vector and 1438 bp for 
the insert), lending potential to the presence of the DNA vaccine.  
 
FACS Analysis confirmed the presence of viable dendritic cells capable of transducing presented 
DNA into Class I MHC molecules. Whereas the control cell group exhibited 6% fluorescence for 
pMax GFP and 9% for PE, cells labeled with CD11c-PE antibodies exhibited 84.8% for PE, a 
significant difference. Thus, cells labeled with CD11c-PE antibodies would fluoresce 
significantly more than if unlabeled. Additionally, cells isolated from mouse bone marrow and 
nucleofected with pMax-RFP were 23.8% effective at transducing presented DNA to the surface. 
Cells isolated from mouse bone marrow and  nucleofected with pMax-GFP were 49% effective 
at transducing presented DNA to the surface. The same cells were 95.5% effectively labeled with 
CD11c-PE antibodies. Therefore, cells tranduced with DNA would be 46.8% effective at 
fluorescing CD11c-PE antibodies labeling the antigen expressed in dendritic cells. Efficacy of 
transduction and antibody labeling could vary upon multiple attempts, however the presence of 
viable dendritic cells is certain.  
 
With further pursuit, a DNA vaccine capable of targeting guanylyl cyclase in the systemic body 
could be developed and administered in vitro to dendritic cells harvested from the organism. The 
harvested dendritic cells could be matured with LPS, nucleofected with the constructed plasmid, 
and would express guanylyl cyclase as an antigen on class I MHC molecules. Such antigen-
presenting dendritic cells would activate killer T cells targeting cells expressing guanylyl 
cyclase. Such a vaccine would be effective at targeting metastatic adenocarcinoma, known for 
overexpression of guanylyl cyclase. Such treatments would begin with observing prophylactic 
treatment effectiveness in preventing metastasis compared to that of therapeutic treatment in 
destroying microtumors.  
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